Role of DNA repair in host immune response and inflammation

Mutation Research - Reviews in Mutation Research

Volumn 763, Issue , 2015, Pages 246-257

  Fontes, Fabrícia Lima ^a   Pinheiro, Daniele Maria Lopes ^a   Oliveira, Ana Helena Sales de ^a   Oliveira, Rayssa Karla de Medeiros ^a   Lajus, Tirzah Braz Petta ^a,b   Agnez Lima, Lucymara Fassarella ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b Hospital Liga Norte Riograndense Contra o Câncer   (Brazil)

Author keywords

Adaptive immunity; DNA damage; DNA repair; Infectious diseases; Inflammatory response; Innate immunity

Indexed keywords

CELL ADHESION MOLECULE; CELL DNA; CHEMOKINE; CYTOKINE; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RESVERATROL;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL MATURATION; DNA DAMAGE; DNA RECOMBINATION; DNA REPAIR; GENE REARRANGEMENT; GENETIC VARIABILITY; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNOREACTIVITY; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOMATIC HYPERMUTATION; T LYMPHOCYTE; TRANSCRIPTION REGULATION; VDJ RECOMBINATION; VIRUS INFECTION; VIRUS REPLICATION; COMMUNICABLE DISEASE; GENETICS; IMMUNOLOGY; METABOLISM; VIROLOGY;

COMMUNICABLE DISEASES; DNA DAMAGE; DNA REPAIR; DNA REPAIR ENZYMES; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, INNATE; INFLAMMATION; OXIDATIVE STRESS;

EID: 84924973514     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2014.11.004     Document Type: Review

References (217)

1. Medzhitov R., Janeway C.J. Advances in immunology: innate immunity. New Engl. J. Med. 2000, 343:338-344.
2. Janeway C.A., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002, 20:197-216.
3. Pasare C., Medzhitov R. Toll-like receptors and acquired immunity. Semin. Immunol. 2004, 16:23-26.
4. Takeuchi O., Akira S. Signaling pathways activated by microorganisms. Curr. Opin. Cell Biol. 2007, 19:185-191.
5. Mancuso G., Gambuzza M., Midiri A., Biondo C., Papasergi S., Akira S., Teti G., Beninati C. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat. Immunol. 2009, 10:U587-U593.
6. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
7. Majdalawieh A., Ro H.S. Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages. Mediators Inflamm. 2010, 2010:823821.
8. Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4:499-511.
9. Bendelac A., Bonneville M., Kearney J.F. Autoreactivity by design: innate B and T lymphocytes. Nat. Rev. Immunol. 2001, 1:177-186.
10. Yachie A., Konno A., Ohta K., Wada T., Seki H., Taniguchi N., Miyawaki T. Delineation of producing ability of Igg and Iga subclasses by naive B-cells in newborn-infants and adult individuals. Clin. Exp. Immunol. 1995, 102:204-209.
11. Klein M., Koedel U., Pfister H.W. Oxidative stress in pneumococcal meningitis: a future target for adjunctive therapy?. Prog. Neurobiol. 2006, 80:269-280.
12. da Silva T.A., Fontes F.L., Coutinho L.G., de Souza F.R., de Melo J.T., de Souto J.T., Leib S.L., Agnez-Lima L.F. SNPs in DNA repair genes associated to meningitis and host immune response. Mutat. Res. 2011, 713:39-47.
13. Boonstra A., van Oudenaren A., Baert M., van Steeg H., Leenen P.J., van der Horst G.T., Hoeijmakers J.H., Savelkoul H.F., Garssen J. Differential ultraviolet-B-induced immunomodulation in XPA, XPC, and CSB DNA repair-deficient mice. J. Invest. Dermatol. 2001, 117:141-146.
14. Melis J.P., van Steeg H., Luijten M. Oxidative DNA damage and nucleotide excision repair. Antioxid. Redox Signal. 2012, 18:2409-2419.
15. Xu Y. DNA damage: a trigger of innate immunity but a requirement for adaptive immune homeostasis. Nat. Rev. Immunol. 2006, 6:261-270.
16. O'Driscoll M., Jeggo P. Immunological disorders and DNA repair. Mutat. Res. 2002, 509:109-126.
17. Saeidnia S., Abdollahi M. Toxicological and pharmacological concerns on oxidative stress and related diseases. Toxicol. Appl. Pharmacol. 2013, 273:442-455.
18. Scheld W.M., Koedel U., Nathan B., Pfister H.W. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J. Infect. Dis. 2002, 186:S225-S233.
19. Grahn A., Hagberg L., Nilsson S., Blennow K., Zetterberg H., Studahl M. Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections. J. Neurol. 2013, 260:1813-1821.
20. de Oliveira L.R., Cezario G.A., de Lima C.R., Nicolete V.C., Peresi E., de Sibio M.T., Picka M.C., Calvi S.A. DNA damage and nitric oxide production in mice following infection with L. chagasi. Mutat. Res. 2011, 723:177-181.
21. Wolters S., Schumacher B. Genome maintenance and transcription integrity in aging and disease. Front. Genet. 2013, 4:19.
22. Brookes P.S., Yoon Y.S., Robotham J.L., Anders M.W., Sheu S.S. Calcium ATP and ROS: a mitochondrial love-hate triangle. Am. J. Physiol. Cell. Ph. 2004, 287:C817-C833.
23. Kienhofer J., Haussler D.J.F., Ruckelshausen F., Muessig E., Weber K., Pimentel D., Ullrich V., Burkle A., Bachschmid M.M. Association of mitochondrial antioxidant enzymes with mitochondrial DNA as integral nucleoid constituents. FASEB J. 2009, 23:2034-2044.
24. Chung H.S., Kim H., Lee G., Shin M., Hong M., Kim Y., Bae H. Phenelzine potentiates production of nitric oxide and tumor necrosis factor-alpha via NF-kappa B pathway in LPS-activated BV-2 microgia cell line. Mol. Cell. Toxicol. 2009, 5:48.
25. Uttara B., Singh A.V., Zamboni P., Mahajan R.T. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 2009, 7:65-74.
26. Chiba T., Marusawa H., Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012, 143:550-563.
27. De Chiara G., Marcocci M.E., Sgarbanti R., Civitelli L., Ripoli C., Piacentini R., Garaci E., Grassi C., Palamara A.T. Infectious agents and neurodegeneration. Mol. Neurobiol. 2012, 46:614-638.
28. Agnez-Lima L.F., Melo J.T., Silva A.E., Oliveira A.H., Timoteo A.R., Lima-Bessa K.M., Martinez G.R., Medeiros M.H., Di Mascio P., Galhardo R.S., Menck C.F. DNA damage by singlet oxygen and cellular protective mechanisms. Mutat. Res. 2012, 751:15-28.
29. Cadet J., Wagner J.R. Oxidatively generated base damage to cellular DNA by hydroxyl radical and one-electron oxidants: similarities and differences. Arch. Biochem. Biophys. 2014, 557:47-54.
30. Schoonbroodt S., Ferreira V., Best-Belpomme M., Boelaert J.R., Legrand-Poels S., Korner M., Piette J. Crucial role of the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of I kappa B alpha in NF-kappa B activation by an oxidative stress. J. Immunol. 2000, 164:4292-4300.
31. Gloire G., Legrand-Poels S., Piette J. NF-kappa B activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 2006, 72:1493-1505.
32. Habraken Y., Piette J. NF-kappaB activation by double-strand breaks. Biochem. Pharmacol. 2006, 72:1132-1141.
33. Muralidharan S., Mandrekar P. Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation. J. Leukoc. Biol. 2013, 94:1167-1184.
34. Elsen S., Collin-Faure V., Gidrol X., Lemercier C. The opportunistic pathogen Pseudomonas aeruginosa activates the DNA double-strand break signaling and repair pathway in infected cells. Cell. Mol. Life. Sci. 2013, 70:4385-4397.
35. Toller I.M., Neelsen K.J., Steger M., Hartung M.L., Hottiger M.O., Stucki M., Kalali B., Gerhard M., Sartori A.A., Lopes M., Muller A. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14944-14949.
36. Huang T.T., Wuerzberger-Davis S.M., Seufzer B.J., Shumway S.D., Kurama T., Boothman D.A., Miyamoto S. NF-kappa B activation by camptothecin-a linkage between nuclear DNA damage and cytoplasmic signaling events. J. Biol. Chem. 2000, 275:9501-9509.
37. Habraken Y., Piret B., Piette J. S phase dependence and involvement of NF-kappaB activating kinase to NF-kappaB activation by camptothecin. Biochem. Pharmacol. 2001, 62:603-616.
38. Li N.X., Banin S., Quyang H.H., Li G.C., Courtois G., Shiloh Y., Karin M., Rotman G. ATM is required for I kappa B kinase (IKK) activation in response to DNA double strand breaks. J. Biol. Chem. 2001, 276:8898-8903.
39. Chatzinikolaou G., Karakasilioti I., Garinis G.A. DNA damage and innate immunity: links and trade-offs. Trends Immunol. 2014, 35:429-435.
40. Hegde M.L., Mantha A.K., Hazra T.K., Bhakat K.K., Mitra S., Szczesny B. Oxidative genome damage and its repair: implications in aging and neurodegenerative diseases. Mech. Ageing Dev. 2012, 133:157-168.
41. Friedberg E.C., Aguilera A., Gellert M., Hanawalt P.C., Hays J.B., Lehmann A.R., Lindahl T., Lowndes N., Sarasin A., Wood R.D. DNA repair: from molecular mechanism to human disease. DNA Repair 2006, 5:986-996.
42. Jacobs A.L., Schar P. DNA glycosylases: in DNA repair and beyond. Chromosoma 2012, 121:1-20.
43. Mabley J.G., Pacher P., Deb A., Wallace R., Elder R.H., Szabo C. Potential role for 8-oxoguanine DNA glycosylase in regulating inflammation. FASEB J. 2005, 19:290-292.
44. Touati E., Michel V., Thiberge J.M., Ave P., Huerre M., Bourgade F., Klungland A., Labigne A. Deficiency in OGG1 protects against inflammation and mutagenic effects associated with H. pylori infection in mouse. Helicobacter 2006, 11:494-505.
45. Li G.P., Yuan K.F., Yan C.G., Fox J., Gaid M., Breitwieser W., Bansal A.K., Zeng H.W., Gao H.W., Wu M. 8-Oxoguanine-DNA glycosylase 1 deficiency modifies allergic airway inflammation by regulating STAT6 and IL-4 in cells and in mice. Free Radical Biol. Med. 2012, 52:392-401.
46. Boldogh I., Hajas G., Aguilera-Aguirre L., Hegde M.L., Radak Z., Bacsi A., Sur S., Hazra T.K., Mitra S. Activation of ras signaling pathway by 8-oxoguanine DNA glycosylase bound to its excision product, 8-oxoguanine. J. Biol. Chem. 2012, 287:20769-20773.
47. Hajas G., Bacsi A., Aguilera-Aguirre L., Hegde M.L., Tapas K.H., Sur S., Radak Z., Ba X., Boldogh I. 8-Oxoguanine DNA glycosylase-1 links DNA repair to cellular signaling via the activation of the small GTPase Rac1. Free Radical Biol. Med. 2013, 61C:384-394.
48. Ba X., Aguilera-Aguirre L., Rashid Q.T., Bacsi A., Radak Z., Sur S., Hosoki K., Hegde M.L., Boldogh I. The role of 8-oxoguanine DNA glycosylase-1 in inflammation. Int. J. Mol. Sci. 2014, 15:16975-16997.
49. Li G., Yuan K., Yan C., Fox J., Gaid M., Breitwieser W., Bansal A.K., Zeng H., Gao H., Wu M. 8-Oxoguanine-DNA glycosylase 1 deficiency modifies allergic airway inflammation by regulating STAT6 and IL-4 in cells and in mice. Free Radical Biol. Med. 2012, 52:392-401.
50. Ba X., Bacsi A., Luo J., Aguilera-Aguirre L., Zeng X., Radak Z., Brasier A.R., Boldogh I. 8-Oxoguanine DNA glycosylase-1 augments proinflammatory gene expression by facilitating the recruitment of site-specific transcription factors. J. Immunol. 2014, 192:2384-2394.
51. Sun C., Chen H., Guo W., Zhang K., Qi Q., Gu X., Zhu D., Wang Y. A common mutation of the MYH gene is associated with increased DNA oxidation and age-related diseases. Free Radical Biol. Med. 2010, 48:430-436.
52. Cai Z., Guo W., Chen H., Tao J., Cao L., Sun W., Wang Y. Base excision repair gene polymorphisms are associated with inflammation in patients undergoing chronic hemodialysis. Biochem. Biophys. Res. Commun. 2012, 424:611-615.
53. Ando K., Hirao S., Kabe Y., Ogura Y., Sato I., Yamaguchi Y., Wada T., Handa H. A new APE1/Ref-1-dependent pathway leading to reduction of NF-kappa B and AP-1, and activation of their DNA-binding activity. Nucleic Acids Res. 2008, 36:4327-4336.
54. Luo M.H., He H.Z., Kelley M.R., Georgiadis M.M. Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid. Redox Signal. 2010, 12:1247-1269.
55. Lando D., Pongratz I., Poellingers L., Whitelaw M.L. A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1 alpha and the HIF-like factor. J. Biol. Chem. 2000, 275:4618-4627.
56. Kelley M.R., Georgiadis M.M., Fishel M.L. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr. Mol. Pharmacol. 2012, 5:36-53.
57. Thakur S., Sarkar B., Cholia R.P., Gautam N., Dhiman M., Mantha A.K. APE1/Ref-1 as an emerging therapeutic target for various human diseases: phytochemical modulation of its function. Exp. Mol. Med. 2014, 46:e106.
58. Tell G., Damante G., Caldwell D., Kelley M.R. The intracellular localization of APE1/Ref-1: more than a passive phenomenon?. Antioxid. Redox Signal. 2005, 7:367-384.
59. Lee H.M., Yuk J.M., Shin D.M., Yang C.S., Kim K.K., Choi D.K., Liang Z.L., Kim J.M., Jeon B.H., Kim C.D., Lee J.H., Jo E.K. Apurinic/apyrimidinic endonuclease 1 is a key modulator of keratinocyte inflammatory responses. J. Immunol. 2009, 183:6839-6848.
60. O'Hara A.M., Bhattacharyya A., Bai J., Mifflin R.C., Ernst P.B., Mitra S., Crowe S.E. Tumor necrosis factor (TNF)-alpha-induced IL-8 expression in gastric epithelial cells: role of reactive oxygen species and AP endonuclease-1/redox factor (Ref)-1. Cytokine 2009, 46:359-369.
61. Tell G., Quadrifoglio F., Tiribelli C., Kelley M.R. The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid. Redox Signal. 2009, 11:601-619.
62. Perillo B., Ombra M.N., Bertoni A., Cuozzo C., Sacchetti S., Sasso A., Chiariotti L., Malorni A., Abbondanza C., Avvedimento E.V. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science 2008, 319:202-206.
63. Amente S., Bertoni A., Morano A., Lania L., Avvedimento E.V., Majello B. LSD1-mediated demethylation of histone H3 lysine 4 triggers Myc-induced transcription. Oncogene 2010, 29:3691-3702.
64. Krishnakumar R., Kraus W.L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol. Cell 2010, 39:8-24.
65. Bouchard W.J., Rouleau M., Poirier G.G. PARP-1 a determinant of cell survival in response to DNA damage. Exp. Hematol. 2003, 31:446-454.
66. Mangerich A., Burkle A. Pleiotropic cellular functions of PARP1 in longevity and aging: genome maintenance meets inflammation. Oxid. Med. Cell. Longev. 2012, 2012:321653.
67. Zingarelli B., Szabo C., Salzman A.L. Blockade of poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis. Gastroenterology 1999, 116:335-345.
68. Schreiber V., Dantzer F., Ame J.C., de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7:517-528.
69. Sharp C., Warren A., Oshima T., Williams L., Li J.H., Alexander J.S. Poly ADP ribose-polymerase inhibitors prevent the upregulation of ICAM-1 and E-selectin in response to Th1 cytokine stimulation. Inflammation 2001, 25:157-163.
70. Phulwani N.K., Kielian T. Poly(ADP-ribose) polymerases (PARPs) 1-3 regulate astrocyte activation. J. Neurochem. 2008, 106:578-590.
71. Szanto M., Brunyanszki A., Kiss B., Nagy L., Gergely P., Virag L., Bai P. Poly(ADP-ribose) polymerase-2: emerging transcriptional roles of a DNA-repair protein. Cell. Mol. Life Sci. 2012, 69:4079-4092.
72. Krishnakumar R., Gamble M.J., Frizzell K.M., Berrocal J.G., Kininis M., Kraus W.L. Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes. Science 2008, 319:819-821.
73. Timinszky G., Till S., Hassa P.O., Hothorn M., Kustatscher G., Nijmeijer B., Colombelli J., Altmeyer M., Stelzer E.H.K., Scheffzek K., Hottiger M.O., Ladurner A.G. A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nat. Struct. Mol. Biol. 2009, 16:U923-U941.
74. Chou D.M., Adamson B., Dephoure N.E., Tan X., Nottke A.C., Hurov K.E., Gygi S.P., Colaiacovo M.P., Elledge S.J. A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:18475-18480.
75. Horio T., Miyauchi-Hashimoto H., Kuwamoto K., Horiki S., Okamoto H., Tanaka K. Photobiologic and photoimmunologic characteristics of XPA gene-deficient mice. J. Invest. Derm. Symp. P. 2001, 6:58-63.
76. Mullenders L.H.F., Berneburg M. Photoimmunology and nucleotide excision repair: impact of transcription coupled and global genome excision repair. J. Photochem. Photobiol. B 2001, 65:97-100.
77. Vink A.A., Moodycliffe A.M., Shreedhar V., Ullrich S.E., Roza L., Yarosh D.B., Kripke M.L. The inhibition of antigen-presenting activity of dendritic cells resulting from UV irradiation of murine skin is restored by in vitro photorepair of cyclobutane pyrimidine dimers. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:5255-5260.
78. Nishigori C., Yarosh D.B., Ullrich S.E., Vink A.A., Bucana C.D., Roza L., Kripke M.L. Evidence that DNA damage triggers interleukin 10 cytokine production in UV-irradiated murine keratinocytes. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:10354-10359.
79. Connor A.O., Nishigori C., Yarosh D., Alas L., Kibitel J., Burley L., Cox P., Bucana C., Ullrich S., Kripke M. DNA double strand breaks in epidermal cells cause immune suppression in vivo and cytokine production in vitro. J. Immunol. 1996, 157:271-278.
80. Petit-Frere C., Clingen P.H., Grewe M., Krutmann J., Roza L., Arlett C.F., Green M.H.L. Induction of interleukin-6 production by ultraviolet radiation in normal human epidermal keratinocytes and in a human keratinocyte cell line is mediated by DNA damage. J. Invest. Dermatol. 1998, 111:354-359.
81. Muller H.K., Woods G.M. Ultraviolet radiation effects on the proteome of skin cells. Adv. Exp. Med. Biol. 2013, 990:111-119.
82. Napirei M., Karsunky H., Zevnik B., Stephan H., Mannherz H.G., Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 2000, 25:177-181.
83. Le May N., Mota-Fernandes D., Vélez-Cruz R., Iltis I., Biard D., Egly J.M. NER factors are recruited to active promoters and facilitate chromatin modification for transcription in the absence of exogenous genotoxic attack. Mol. Cell. 2010, 38:54-66.
84. Le May N., Fradin D., Iltis I., Bougneres P., Egly J.M. XPG and XPF endonucleases trigger chromatin looping and DNA demethylation for accurate expression of activated genes. Mol. Cell 2012, 47:622-632.
85. Conforti G., Nardo T., D'Incalci H., Stefanini M. Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation. Oncogene 2000, 19:2714-2720.
86. Ljungman M., Zhang F.F. Blockage of RNA polymerase as a possible trigger for UV light-induced apoptosis. Oncogene 1996, 13:823-831.
87. Fousteri M., Vermeulen W., van Zeeland A.A., Mullenders L.H.F. Cockayne syndrome A and B proteins differentially regulate recruitment of chromatin remodeling and repair factors to stalled RNA polymerase II in vivo. Mol. Cell 2006, 23:471-482.
88. Kamiuchi S., Saijo M., Citterio E., de Jager M., Hoeijmakers J.H.J., Tanaka K. Translocation of cockayne syndrome group A protein to the nuclear matrix: possible relevance to transcription-coupled DNA repair. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:201-206.
89. Klungland A., Hoss M., Gunz D., Constantinou A., Clarkson S.G., Doetsch P.W., Bolton P.H., Wood R.D., Lindahl T. Base excision repair of oxidative DNA damage activated by XPG protein. Mol. Cell 1999, 3:33-42.
90. Yi Y.W., Kang H.J., Bae I. BRCA1 and oxidative stress. Cancers (Basel) 2014, 6:771-795.
91. Venkitaraman A.R. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J. Cell Sci. 2001, 114:3591-3598.
92. Mullan P.B., Quinn J.E., Harkin D.P. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006, 25:5854-5863.
93. Rosen E.M., Fan S.J., Ma Y.X. BRCA1 regulation of transcription. Cancer Lett. 2006, 236:175-185.
94. Buckley N.E., Hosey A.M., Gorski J.J., Purcell J.W., Mulligan J.M., Harkin D.P., Mullan P.B. L3RCA1 regulates IFN-gamma signaling through a mechanism involving the type IIFNs. Mol. Cancer Res. 2007, 5:261-270.
95. Figueiredo N., Chora A., Raquel H., Pejanovic N., Pereira P., Hartleben B., Neves-Costa A., Moita C., Pedroso D., Pinto A., Marques S., Faridi H., Costa P., Gozzelino R., Zhao J.L., Soares M.P., Gama-Carvalho M., Martinez J., Zhang Q., Doring G., Grompe M., Simas J.P., Huber T.B., Baltimore D., Gupta V., Green D.R., Ferreira J.A., Moita L.F. Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity 2013, 39:874-884.
96. Duprez L., Takahashi N., van Hauwermeiren F., Vandendriessche B., Goossens V., Vanden Berghe T., Declercq W., Libert C., Cauwels A., Vandenabeele P. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity 2011, 35:908-918.
97. Chaudhary M.W., Al-Baradie R.S. Ataxia-telangiectasia: future prospects. Appl. Clin. Genet. 2014, 7:159-167.
98. Nikolich-Zugich J., Slifka M.K., Messaoudi I. The many important facets of T-cell repertoire diversity. Nat. Rev. Immunol. 2004, 4:123-132.
99. Herzog S., Jumaa H. Self-recognition and clonal selection: autoreactivity drives the generation of B cells. Curr. Opin. Immunol. 2012, 24:166-172.
100. Stavnezer J., Bjorkman A., Du L., Cagigi A., Pan-Hammarstrom Q. Mapping of switch recombination junctions, a tool for studying DNA repair pathways during immunoglobulin class switching. Adv. Immunol. 2010, 108:45-109.
101. Chen Z., Wang J.H. Generation and repair of AID-initiated DNA lesions in B lymphocytes. Front. Med. 2014, 8:201-216.
102. Woodbine L., Gennery A.R., Jeggo P.A. The clinical impact of deficiency in DNA non-homologous end-joining. DNA Repair 2014, 16:84-96.
103. Bassing C.H., Swat W., Alt F.W. The mechanism and regulation of chromosomal V(D)J recombination. Cell 2002, 109:S45-S55.
104. Bednarski J.J., Sleckman B.P. Lymphocyte development: integration of DNA damage response signaling. Adv. Immunol. 2012, 116:175-204.
105. Fugmann S.D., Lee A.I., Shockett P.E., Villey I.J., Schatz D.G. The rag proteins and V(D)J recombination: complexes, ends, and transposition. Annu. Rev. Immunol. 2000, 18:495-527.
106. Krangel M.S. T cell development: better living through chromatin. Nat. Immunol. 2007, 8:686-693.
107. Osipovich O., Oltz E.M. Regulation of antigen receptor gene assembly by genetic-epigenetic crosstalk. Semin. Immunol. 2010, 22:313-322.
108. Lieber M.R. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu. Rev. Biochem. 2010, 79:181-211.
109. Revy P., Buck D., le Deist F., de Villartay J.P. The repair of DNA damages/modifications during the maturation of the immune system: lessons from human primary immunodeficiency disorders and animal models. Adv. Immunol. 2005, 87:237-295.
110. Soulas-Sprauel P., Rivera-Munoz P., Malivert L., Le Guyader G., Abramowski V., Revy P., de Villartay J.P. V(D)J and immunoglobulin class switch recombinations: a paradigm to study the regulation of DNA end-joining. Oncogene 2007, 26:7780-7791.
111. Perkins E.J., Nair A., Cowley D.O., Van Dyke T., Chang Y., Ramsden D.A. Sensing of intermediates in V(D)J recombination by ATM. Genes Dev. 2002, 16:159-164.
112. Callén E., Jankovic M., Difilippantonio S., Daniel J.A., Chen H.T., Celeste A., Pellegrini M., McBride K., Wangsa D., Bredemeyer A.L., Sleckman B.P., Ried T., Nussenzweig M., Nussenzweig A. ATM prevents the persistence and propagation of chromosome breaks in lymphocytes. Cell 2007, 130:63-75.
113. Nakamura K., Kato A., Kobayashi J., Yanagihara H., Sakamoto S., Oliveira D.V., Shimada M., Tauchi H., Suzuki H., Tashiro S., Zou L., Komatsu K. Regulation of homologous recombination by RNF20-dependent H2B ubiquitination. Mol. Cell 2011, 41:515-528.
114. Ramiro A.R., Jankovic M., Callen E., Difilippantonio S., Chen H.T., McBride K.M., Eisenreich T.R., Chen J., Dickins R.A., Lowe S.W., Nussenzweig A., Nussenzweig M.C. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 2006, 440:105-109.
115. Ramiro A.R., Jankovic M., Eisenreich T., Difilippantonio S., Chen-Kiang S., Muramatsu M., Honjo T., Nussenzweig A., Nussenzweig M.C. AID is required for c-myc/IgH chromosome translocations in vivo. Cell 2004, 118:431-438.
116. Benedict C.L., Gilfillan S., Thai T.H., Kearney J.F. Terminal deoxynucleotidyl transferase and repertoire development. Immunol. Rev. 2000, 175:150-157.
117. Boboila C., Alt F.W., Schwer B. Classical and alternative end-joining pathways for repair of lymphocyte-specific and general DNA double-strand breaks. Adv. Immunol. 2012, 116:1-49.
118. Pinaud E., Marquet M., Fiancette R., Peron S., Vincent-Fabert C., Denizot Y., Cogne M. The IgH locus 3' regulatory region: pulling the strings from behind. Adv. Immunol. 2011, 110:27-70.
119. Krangel M.S. Mechanics of T cell receptor gene rearrangement. Curr. Opin. Immunol. 2009, 21:133-139.
120. Bradley L.M., Migration T-lymphocyte effector function. Curr. Opin. Immunol. 2003, 15:343-348.
121. Kumar R., DiMenna L.J., Chaudhuri J., Evans T. Biological function of activation-induced cytidine deaminase (AID). Biomed. J. 2014, 37:269-283.
122. Stavnezer J., Guikema J.E., Schrader C.E. Mechanism and regulation of class switch recombination. Annu. Rev. Immunol. 2008, 26:261-292.
123. Peled J.U., Kuang F.L., Iglesias-Ussel M.D., Roa S., Kalis S.L., Goodman M.F., Scharff M.D. The biochemistry of somatic hypermutation. Annu. Rev. Immunol. 2008, 26:481-511.
124. Imai K., Slupphaug G., Lee W.I., Revy P., Nonoyama S., Catalan N., Yel L., Forveille M., Kavli B., Krokan H.E., Ochs H.D., Fischer A., Durandy A. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat. Immunol. 2003, 4:1023-1028.
125. Guikema J.E., Linehan E.K., Tsuchimoto D., Nakabeppu Y., Strauss P.R., Stavnezer J., Schrader C.E. APE1- and APE2-dependent DNA breaks in immunoglobulin class switch recombination. J. Exp. Med. 2007, 204:3017-3026.
126. Sabouri Z., Okazaki I.M., Shinkura R., Begum N., Nagaoka H., Tsuchimoto D., Nakabeppu Y., Honjo T. Apex2 is required for efficient somatic hypermutation but not for class switch recombination of immunoglobulin genes. Int. Immunol. 2009, 21:947-955.
127. Masani S., Han L., Yu K. Apurinic/apyrimidinic endonuclease 1 is the essential nuclease during immunoglobulin class switch recombination. Mol. Cell. Biol. 2013, 33:1468-1473.
128. Ucher A.J., Linehan E.K., Teebor G.W., Schrader C.E., Stavnezer J. The DNA glycosylases Ogg1 and Nth1 do not contribute to Ig class switching in activated mouse splenic B cells. PLoS One 2012, 7:e36061.
129. Winter D.B., Phung Q.H., Zeng X., Seeberg E., Barnes D.E., Lindahl T., Gearhart P.J. Normal somatic hypermutation of Ig genes in the absence of 8-hydroxyguanine-DNA glycosylase. J. Immunol. 2003, 170:5558-5562.
130. Kotnis A., Du L., Liu C., Popov S.W., Pan-Hammarstrom Q. Non-homologous end joining in class switch recombination: the beginning of the end. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2009, 364:653-665.
131. Sale J.E., Batters C., Edmunds C.E., Phillips L.G., Simpson L.J., Szüts D. Timing matters: error-prone gap filling and translesion synthesis in immunoglobulin gene hypermutation. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2009, 364:595-603.
132. Krijger P.H., Tsaalbi-Shtylik A., Wit N., van den Berk P.C., de Wind N., Jacobs H. Rev1 is essential in generating G to C ransversions downstream of the Ung2 pathway but not the Msh2+Ung2 hybrid pathway. Eur. J. Immunol. 2013, 43:2765-2770.
133. Stavnezer J., Linehan E.K., Thompson M.R., Habboub G., Ucher A.J., Kadungure T., Tsuchimoto D., Nakabeppu Y., Schrader C.E. Differential expression of APE1 and APE2 in germinal centers promotes error-prone repair and A:T mutations during somatic hypermutation. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:9217-9222.
134. Bryant H.E., Petermann E., Schultz N., Jemth A.S., Loseva O., Issaeva N., Johansson F., Fernandez S., McGlynn P., Helleday T. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 2009, 28:2601-2615.
135. Ambrose H.E., Willimott S., Beswick R.W., Dantzer F., de Murcia J.M., Yelamos J., Wagner S.D. Poly(ADP-ribose) polymerase-1 (Parp-1)-deficient mice demonstrate abnormal antibody responses. Immunology 2009, 127:178-186.
136. Dorsett Y., Robbiani D.F., Jankovic M., Reina-San-Martin B., Eisenreich T.R., Nussenzweig M.C. A role for AID in chromosome translocations between c-myc and the IgH variable region. J. Exp. Med. 2007, 204:2225-2232.
137. Robert I., Dantzer F., Reina-San-Martin B. Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination. J. Exp. Med. 2009, 206:1047-1056.
138. Lilley C.E., Schwartz R.A., Weitzman M.D. Using or abusing: viruses and the cellular DNA damage response. Trends Microbiol. 2007, 15:119-126.
139. Koganti S., Hui-Yuen J., McAllister S., Gardner B., Grasser F., Palendira U., Tangye S.G., Freeman A.F., Bhaduri-McIntosh S. STAT3 interrupts ATR-Chk1 signaling to allow oncovirus-mediated cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:4946-4951.
140. Skalka A.M., Katz R.A. Retroviral DNA integration and the DNA damage response. Cell Death Differ. 2005, 12:971-978.
141. Daniel R., Ramcharan J., Rogakou E., Taganov K.D., Greger J.G., Bonner W., Nussenzweig A., Katz R.A., Skalka A.M. Histone H2AX is phosphorylated at sites of retroviral DNA integration but is dispensable for postintegration repair. J. Biol. Chem. 2004, 279:45810-45814.
142. Lau A., Swinbank K.M., Ahmed P.S., Taylor D.L., Jackson S.P., Smith G.C.M., O'Connor M.J. Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat. Cell Biol. 2005, 7. 493-U457.
143. Daniel R., Kao G., Taganov K., Greger J.G., Favorova O., Merkel G., Yen T.J., Katz R.A., Skalka A.M. Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage response. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4778-4783.
144. Daniel R., Katz R.A., Merkel G., Hittle J.C., Yen T.J., Skalka A.M. Wortmannin potentiates integrase-mediated killing of lymphocytes and reduces the efficiency of stable transduction by retroviruses. Mol. Cell Biol. 2001, 21:1164-1172.
145. Daniel R., Katz R.A., Skalka A.M. A role for DNA-PK in retroviral DNA integration. Science 1999, 284:644-647.
146. Deng W.S., Roberts S.G.E. TFIIB and the regulation of transcription by RNA polymerase II. Chromosoma 2007, 116:417-429.
147. Yoder K., Sarasin A., Kraemer K., McIlhatton M., Bushman F., Fishel R. The DNA repair genes XPB and XPD defend cells from retroviral infection. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:4622-4627.
148. Lau A., Kanaar R., Jackson S.P., O'Connor M.J. Suppression of retroviral infection by the RAD52 DNA repair protein. EMBO J. 2004, 23:3421-3429.
149. Yoder K.E., Espeseth A., Wang X.H., Fang Q.M., Russo M.T., Lloyd R.S., Hazuda D., Sobol R.W., Fishel R. The base excision repair pathway is required for efficient lentivirus integration. PLoS One 2011, 6:e17862.
150. Bush K. The coming of age of antibiotics: discovery and therapeutic value. Ann. N.Y. Acad. Sci. 2010, 1213:1-4.
151. Zhu W., Zhang Y.H., Sinko W., Hensler M.E., Olson J., Molohon K.J., Lindert S., Cao R., Li K., Wang K., Wang Y., Liu Y.L., Sankovsky A., de Oliveira C.A.F., Mitchell D.A., Nizet V., McCammon J.A., Oldfield E. Antibacterial drug leads targeting isoprenoid biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:123-128.
152. Zaffiri L., Gardner J., Toledo-Pereyra L.H. History of antibiotics. From salvarsan to cephalosporins. J. Invest. Surg. 2012, 25:67-77.
153. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to use in the isolation of B. influenzae. 1929. Bull. World Health Organ. 2001, 79:780-790.
154. Amedei A., D'Elios M.M. New therapeutic approaches by using microorganism-derived compounds. Curr. Med. Chem. 2012, 19:3822-3840.
155. Rennie R.P. Current and future challenges in the development of antimicrobial agents, Handb. Exp. Pharmacol. 2012, 211:45-46.
156. Farrell D.J., Castanheira M., Mendes R.E., Sader H.S., Jones R.N. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clin. Infect. Dis. 2012, 55(Suppl. 3):S206-S214.
157. Maron B.A., Michel T. Subcellular localization of oxidants and redox modulation of endothelial nitric oxide synthase. Circ. J. 2012, 76:2497-2512.
158. Valko M., Leibfritz D., Moncol J., Cronin M.T.D., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell. B 2007, 39:44-84.
159. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82:47-95.
160. Leppänen T., Tuominen R.K., Moilanen E. Protein kinase C and its inhibitors in the regulation of inflammation: inducible nitric oxide synthase as an example. Basic Clin. Pharmacol. Toxicol. 2014, 114:37-43.
161. Miesel R., Kurpisz M., Kroger H. Modulation of Inflammatory arthritis by inhibition of poly(Adp Ribose) polymerase. Inflammation 1995, 19:379-387.
162. Suzuki Y., Masini E., Mazzocca C., Cuzzocrea S., Ciampa A., Suzuki H., Bani D. Inhibition of poly(ADP-ribose) polymerase prevents allergen-induced asthma-like reaction in sensitized guinea pigs. J. Pharmacol. Exp. Ther. 2004, 311:1241-1248.
163. Jijon H.B., Churchill T., Malfair D., Wessler A., Jewell L.D., Parsons H.G., Madsen K.L. Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis. Am. J. Physiol. Gastr. L. 2000, 279:G641-G651.
164. Chiarugi A. Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. Br. J. Pharmacol. 2002, 137:761-770.
165. Scott G.S., Kean R.B., Mikheeva T., Fabis M.J., Mabley J.G., Szabo C., Hooper D.C. The therapeutic effects of PJ34 [N-(6-oxo-5,6dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J. Pharmacol. Exp. Ther. 2004, 310:1053-1061.
166. Scott G.S., Hake P., Kean R.B., Virag L., Szabo C., Hooper D.C. Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis. J. Neuroimmunol. 2001, 117:78-86.
167. Masutani M., Nakagama H., Sugimura T. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease. Cell. Mol. Life Sci. 2005, 62:769-783.
168. Kameoka M., Ota K., Tetsuka T., Tanaka Y., Itaya A., Okamoto T., Yoshihara K. Evidence for regulation of NF-kappa B by poly(ADP-ribose) polymerase. Biochem. J. 2000, 346:641-649.
169. Hasko G., Mabley J.G., Nemeth Z.H., Pacher P., Deitch E.A., Szabo C. Poly (ADP-ribose) polymerase is a regulator of chemokine production: relevance for the pathogenesis of shock and inflammation. Mol. Med. 2002, 8:283-289.
170. Zingarelli B., Salzman A.L., Szabo C. Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ. Res. 1998, 83:85-94.
171. Ha H.C., Hester L.D., Snyder S.H. Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:3270-3275.
172. Andreone T.L., O'Connor M., Denenberg A., Hake P.W., Zingarelli B. Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts. J. Immunol. 2003, 170:2113-2120.
173. Koedel U., Winkler F., Angele B., Fontana T., Pfister H.W. Meningitis-associated central nervous system complications are mediated by the activation of poly(ADP-ribose) polymerase. J. Cerebr. Blood F. Met. 2002, 22:39-49.
174. Aldinucci A., Gerlini G., Fossati S., Cipriani G., Ballerini C., Biagioli T., Pimpinelli N., Borgognoni L., Massacesi L., Moroni F., Chiarugi A. A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. J. Immunol. 2007, 179:305-312.
175. Woon E.C., Threadgill M.D. Poly(ADP-ribose)polymerase inhibition-where now?. Curr. Med. Chem. 2005, 12:2373-2392.
176. Shockett P., Stavnezer J. Inhibitors of poly(ADP-ribose) polymerase increase antibody class switching. J. Immunol. 1993, 151:6962-6976.
177. Zhang Y., Zhang L., Song Z., Sun D.L., Liu H.R., Fu S.B., Liu D.R., Liu P. Genetic polymorphisms in DNA repair genes OGG1, APE1, XRCC1, and XPD and the risk of age-related cataract. Ophthalmology 2012, 119:900-906.
178. Sultana R., McNeill D.R., Abbotts R., Mohammed M.Z., Zdzienicka M.Z., Qutob H., Seedhouse C., Laughton C.A., Fischer P.M., Patel P.M., Wilson D.M., Madhusudan S. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int. J. Cancer 2012, 131:2433-2444.
179. Raffoul J.J., Heydari A.R., Hillman G.G. DNA repair cancer therapy: targeting APE1/Ref-1 using dietary agents. J. Oncol. 2012, 2012:370481.
180. Jiang Y.L., Guo C.L., Fishel M.L., Wang Z.Y., Vasko M.R., Kelley M.R. Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions. DNA Repair 2009, 8:1273-1282.
181. Nyland R.L., Luo M., Kelley M.R., Borch R.F. Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1 (Ape1/ref-1). J. Med. Chem. 2010, 53:1200-1210.
182. Hiramoto M., Shimizu N., Sugimoto K., Tang J., Kawakami Y., Ito M., Aizawa S., Tanaka H., Makino I., Handa H. Nuclear targeted suppression of NF-kappa B activity by the novel quinone derivative E3330. J. Immunol. 1998, 160:810-819.
183. Shimizu N., Sugimoto K., Tang J., Nishi T., Sato I., Hiramoto M., Aizawa S., Hatakeyama M., Ohba R., Hatori H., Yoshikawa T., Suzuki F., Oomori A., Tanaka H., Kawaguchi H., Watanabe H., Handa H. High-performance affinity beads for identifying drug receptors. Nat. Biotechnol. 2000, 18:877-881.
184. Nishi T., Shimizu N., Hiramoto M., Sato I., Yamaguchi Y., Hasegawa M., Aizawa S., Tanaka H., Kataoka K., Watanabe H., Handa H. Spatial redox regulation of a critical cysteine residue of NF-kappa B in vivo. J. Biol. Chem. 2002, 277:44548-44556.
185. Jedinak A., Dudhgaonkar S., Kelley M.R., Sliva D. Apurinic/apyrimidinic endonuclease 1 regulates inflammatory response in macrophages. Anticancer Res. 2011, 31:379-385.
186. Manvilla B.A., Wauchope O., Seley-Radtke K.L., Drohat A.C. NMR studies reveal an unexpected binding site for a redox inhibitor of AP endonuclease 1. Biochemistry 2011, 50:10540-10549.
187. Angeloni C., Hrelia S. Quercetin reduces inflammatory responses in LPS-stimulated cardiomyoblasts. Oxid. Med. Cell. Longev. 2012, 2012:837104.
188. Koehn F.E., Carter G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discovery 2005, 4:206-220.
189. Ademiluyi A.O., Oboh G., Ogunsuyi O.B., Akinyemi A.J. Attenuation of gentamycin-induced nephrotoxicity in rats by dietary inclusion of ginger (Zingiber officinale) and turmeric (Curcuma longa) rhizomes. Nutr. Health. 2012, 21:209-218.
190. Cekmen M., Otunctemur A., Ozbek E., Cakir S.S., Dursun M., Polat E.C., Somay A., Ozbay N. Pomegranate extract attenuates gentamicin-induced nephrotoxicity in rats by reducing oxidative stress. Ren. Fail. 2013, 35:268-274.
191. Butler M.S. The role of natural product chemistry in drug discovery. J. Nat. Prod. 2004, 67:2141-2153.
192. Aboul-Enein H.Y., Berczynski P., Kruk I. Phenolic compounds: the role of redox regulation in neurodegenerative disease and cancer. Mini Rev. Med. Chem. 2013, 13:385-398.
193. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
194. Kris-Etherton P.M., Hecker K.D., Bonanome A., Coval S.M., Binkoski A.E., Hilpert K.F., Griel A.E., Etherton T.D. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am. J. Med. 2002, 113:71-88.
195. King R.E., Kent K.D., Bomser J.A. Resveratrol reduces oxidation and proliferation of human retinal pigment epithelial cells via extracellular signal-regulated kinase inhibition. Chem. Biol. Interact. 2005, 151:143-149.
196. Kim I.J., Beck H.N., Lein P.J., Higgins D. Interferon gamma induces retrograde dendritic retraction and inhibits synapse formation. J. Neurosci. 2002, 22:4530-4539.
197. Cerqueira A.M., Khaper N., Lees S.J., Ulanova M. The antioxidant resveratrol down-regulates inflammation in an in-vitro model of Pseudomonas aeruginosa infection of lung epithelial cells. Can. J. Physiol. Pharmacol. 2013, 91:248-255.
198. Zang N., Xie X., Deng Y., Wu S., Wang L., Peng C., Li S., Ni K., Luo Y., Liu E. Resveratrol-mediated gamma interferon reduction prevents airway inflammation and airway hyperresponsiveness in respiratory syncytial virus-infected immunocompromised mice. J. Virol. 2011, 85:13061-13068.
199. Jiang L., Gu Y., Ye J., Liu F., Zhao Y., Wang C., Xu Y., Cao X., Zhang L., Dong W., Li F., Wang J., Wang H., Li Q. Resveratrol prevents hepatic steatosis induced by hepatitis C virus core protein. Biotechnol. Lett. 2012, 34:2205-2212.
200. Fantini D., Vascotto C., Deganuto M., Bivi N., Gustincich S., Marcon G., Quadrifoglio F., Damante G., Bhakat K.K., Mitra S., Tell G. APE1/Ref-1 regulates PTEN expression mediated by Egr-1. Free Radical Res. 2008, 42:20-29.
201. Das S., Das D.K. Anti-inflammatory responses of resveratrol. Inflamm. Allergy Drug Targets 2007, 6:168-173.
202. Yang Z., Yang S., Misner B.J., Chiu R., Liu F., Meyskens F.L. Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonulcease-1/redox factor-1, which is inhibited by resveratrol. Mol. Cancer Ther. 2008, 7:3751-3760.
203. Athar M., Back J.H., Tang X., Kim K.H., Kopelovich L., Bickers D.R., Kim A.L., Resveratrol A review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharm. 2007, 224:274-283.
204. Shankar S., Singh G., Srivastava R.K. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front. Biosci. 2007, 12:4839-4854.
205. de la Lastral C.A., Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem. Soc. T. 2007, 35:1156-1160.
206. Abraham J., Johnson R.W. Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice. Rejuv. Res. 2009, 12:445-453.
207. Zhang Y., Wang J., Xiang D.B., Wang D., Xin X.Y. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor. Int. J. Oncol. 2009, 35:1069-1079.
208. Yang S., Irani K., Heffron S.E., Jurnak F., Meyskens F.L. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther. 2005, 4:1923-1935.
209. Yamamori T., DeRicco J., Naqvi A., Hoffman T.A., Mattagajasingh I., Kasuno K., Jung S.B., Kim C.S., Irani K. SIRT1 deacetylates APE1 and regulates cellular base excision repair. Nucleic Acids Res. 2010, 38:832-845.
210. Baldwin E.L., Osheroff N. Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agents 2005, 5:363-372.
211. Yarchoan R., Pluda J.M., Perno C.F., Mitsuya H., Thomas R.V., Wyvill K.M., Broder S. Initial clinical-experience with dideoxynucleosides as single agents and in combination therapy. Ann. N.Y. Acad. Sci. 1990, 616:328-343.
212. McGuire J.J. Anticancer antifolates: current status and future directions. Curr. Pharm. Des. 2003, 9:2593-2613.
213. Piliero P.J. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. JAIDS-J. Acq. Imm. Def. 2004, 37:S2-S12.
214. Berdis A.J. DNA polymerases as therapeutic targets. Biochemistry 2008, 47:8253-8260.
215. Sanders M.S., van Well G.T., Ouburg S., Morre S.A., van Furth A.M. Genetic variation of innate immune response genes in invasive pneumococcal and meningococcal disease applied to the pathogenesis of meningitis. Genes Immun. 2011, 12:321-334.
216. Rodier F., Coppe J.P., Patil C.K., Hoeijmakers W.A., Munoz D.P., Raza S.R., Freund A., Campeau E., Davalos A.R., Campisi J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 2009, 11:973-979.
217. Mattson M.P. Infectious agents and age-related neurodegenerative disorders. Ageing Res. Rev. 2004, 3:105-120.